Head-To-Head Analysis: Aethlon Medical (AEMD) and Its Rivals

Share on StockTwits

Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Aethlon Medical to related companies based on the strength of its risk, profitability, analyst recommendations, earnings, valuation, institutional ownership and dividends.

Profitability

This table compares Aethlon Medical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aethlon Medical N/A -126.58% -96.36%
Aethlon Medical Competitors -206.30% -32.89% -15.19%

Insider and Institutional Ownership

6.9% of Aethlon Medical shares are owned by institutional investors. Comparatively, 59.0% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.6% of Aethlon Medical shares are owned by insiders. Comparatively, 14.6% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Aethlon Medical and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aethlon Medical $150,000.00 -$5.67 million -2.39
Aethlon Medical Competitors $1.08 billion $109.59 million 25.13

Aethlon Medical’s competitors have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Aethlon Medical has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Aethlon Medical’s competitors have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Aethlon Medical and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aethlon Medical 0 0 1 0 3.00
Aethlon Medical Competitors 115 736 1089 51 2.54

Aethlon Medical presently has a consensus price target of $3.00, suggesting a potential upside of 172.73%. As a group, “Analytical instruments” companies have a potential upside of 7.69%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Aethlon Medical is more favorable than its competitors.

Summary

Aethlon Medical competitors beat Aethlon Medical on 8 of the 13 factors compared.

Aethlon Medical Company Profile

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply